Barclays Maintains Overweight on Revolution Medicines, Raises Price Target to $60

Benzinga · 09/27 18:08
Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $54 to $60.